Targeting OX40: rocatinlimab-a novel therapy for atopic dermatitis

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Access to Document

Targeting OX40: rocatinlimab—a novel therapy for atopic dermatitis
Final published version, 132 KB
Licence: Taverne
Embargo ends: 25/05/26

@article{f188b8ee2e774ccbb1227f344857f389,

title = "Targeting OX40: rocatinlimab-a novel therapy for atopic dermatitis",

author = "Keneshka Atash and Boesjes, \{Celeste M\} and \{de Bruin-Weller\}, \{Marjolein S\}",

year = "2026",

month = jan,

day = "3",

doi = "10.1016/S0140-6736(25)02152-X",

language = "English",

volume = "407",

pages = "4--5",

journal = "Lancet (London, England)",

issn = "0140-6736",

publisher = "Elsevier",

number = "10523",

}

TY - JOUR

T1 - Targeting OX40

T2 - rocatinlimab-a novel therapy for atopic dermatitis

AU - Atash, Keneshka

AU - Boesjes, Celeste M

AU - de Bruin-Weller, Marjolein S

PY - 2026/1/3

Y1 - 2026/1/3

U2 - 10.1016/S0140-6736(25)02152-X

DO - 10.1016/S0140-6736(25)02152-X

M3 - Comment/Letter to the editor

C2 - 41314224

SN - 0140-6736

VL - 407

SP - 4

EP - 5

JO - Lancet (London, England)

JF - Lancet (London, England)

IS - 10523

ER -